Hadwen, Jeremiah <br/><br/>
VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models.  [electronic resource] 

 -  Orphanet journal of rare diseases  Jan 2014 
 - 4 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1750-1172 
<br/><br/><label>Standard No.: </label>10.1186/1750-1172-9-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Disease Models, Animal<br/>Mice<br/>Muscular Atrophy, Spinal--drug therapy<br/>Peptide Fragments--therapeutic use<br/>Receptors, Vasoactive Intestinal Peptide, Type II--agonists<br/>Survival of Motor Neuron 1 Protein--metabolism<br/>Vasoactive Intestinal Peptide--therapeutic use